Corcept Therapeutics (CORT) vs Cytokinetics (CYTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Corcept Therapeutics (CORT) has outperformed Cytokinetics (CYTK) over the past year, losing 17.7% versus a loss of 22.4%. Over five years, CORT leads with a +196.0% price change compared with +30.1% for CYTK. Cytokinetics is the larger company by market cap ($7.07 billion vs $6.96 billion), about 1.0 times the size.
Corcept Therapeutics converts more of its revenue into profit, with a net margin of 13.1% versus -891.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CORT | CYTK |
|---|---|---|
| Share price | $63.62 | $50.78 |
| Market cap | $6.96B | $7.07B |
| 1-day change | -2.09% | -1.32% |
| YTD return | +82.82% | -20.08% |
| 1-year return | -17.69% | -22.40% |
| 5-year return | +196.04% | +30.11% |
| P/E ratio (TTM) | 47.83 | — |
| Forward P/E | 12.77 | — |
| EPS (TTM) | $1.33 | $-6.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $761.41M | $88.04M |
| Revenue growth (YoY) | +12.79% | +376.56% |
| Net income (latest FY) | $99.65M | $-784.96M |
| Gross margin | 98.30% | — |
| Operating margin | 5.88% | -695.44% |
| Net margin | 13.09% | -891.60% |
| 52-week high | $126.38 | $88.31 |
| 52-week low | $28.66 | $50.32 |
| Distance from 52-week high | -49.66% | -42.50% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +124.14% | +115.48% |
| Average volume | 1.26M | 2.02M |
| Shares outstanding | 109.44M | 139.30M |
| Employees | 730 | 673 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Corcept Therapeutics is more profitable, keeping 13.1 cents of every revenue dollar as net income versus -891.6 cents for Cytokinetics.
- Cytokinetics grew revenue faster in its latest fiscal year (+376.56% vs +12.79%).
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
About Cytokinetics
CYTK stock →Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees
CORT vs CYTK FAQ
Which is bigger, Corcept Therapeutics or Cytokinetics?
Cytokinetics (CYTK) is larger, with a market capitalization of $7.07B compared with $6.96B for Corcept Therapeutics (CORT).
Which stock has performed better over the past year, CORT or CYTK?
CORT returned -17.69% over the past 12 months, compared with -22.40% for CYTK (price return, excluding dividends). Past performance does not predict future results.
Are Corcept Therapeutics and Cytokinetics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.